JPWO2021113958A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021113958A5 JPWO2021113958A5 JP2022534425A JP2022534425A JPWO2021113958A5 JP WO2021113958 A5 JPWO2021113958 A5 JP WO2021113958A5 JP 2022534425 A JP2022534425 A JP 2022534425A JP 2022534425 A JP2022534425 A JP 2022534425A JP WO2021113958 A5 JPWO2021113958 A5 JP WO2021113958A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- bis
- hydrogen
- dimethyloct
- dien
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 70
- 229910052739 hydrogen Inorganic materials 0.000 claims 60
- 239000001257 hydrogen Substances 0.000 claims 57
- 150000001875 compounds Chemical class 0.000 claims 34
- -1 C 1 -C 4 alkyl Chemical group 0.000 claims 30
- 150000002431 hydrogen Chemical class 0.000 claims 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 26
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 11
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 239000002207 metabolite Substances 0.000 claims 8
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 2
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 2
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 claims 2
- 108050007331 Cannabinoid receptor Proteins 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010057852 Nicotine dependence Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- UFEJKYYYVXYMMS-UHFFFAOYSA-N methylcarbamic acid Chemical compound CNC(O)=O UFEJKYYYVXYMMS-UHFFFAOYSA-N 0.000 claims 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- FPBOSUGVPBRYCA-UHFFFAOYSA-N (4-nitrophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C([N+]([O-])=O)C=C1 FPBOSUGVPBRYCA-UHFFFAOYSA-N 0.000 claims 1
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- YZWVMKLQNYGKLJ-UHFFFAOYSA-N 1-[2-[2-(2-ethoxyethoxy)ethoxy]ethoxy]-2-methoxyethane Chemical compound CCOCCOCCOCCOCCOC YZWVMKLQNYGKLJ-UHFFFAOYSA-N 0.000 claims 1
- ZBONBGOYILUGCL-UHFFFAOYSA-N 2,2-dimethylpropanoate Chemical compound CC(C)([CH2+])C([O-])=O ZBONBGOYILUGCL-UHFFFAOYSA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 102000014461 Ataxins Human genes 0.000 claims 1
- 108010078286 Ataxins Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- NGNZTVOBWOMJCQ-UHFFFAOYSA-N C(C(C)(C)C)(=O)OCOC1=C(C(=CC(=C1)C(C)(CCCCCC)C)O)CC=C(CCC=C(C)C)C Chemical compound C(C(C)(C)C)(=O)OCOC1=C(C(=CC(=C1)C(C)(CCCCCC)C)O)CC=C(CCC=C(C)C)C NGNZTVOBWOMJCQ-UHFFFAOYSA-N 0.000 claims 1
- LVJFXUFANJXUON-UHFFFAOYSA-N C(C(C)(C)C)(=O)OCOC1=C(C(=CC(=C1)CCC)O)CC=C(CCC=C(C)C)C Chemical compound C(C(C)(C)C)(=O)OCOC1=C(C(=CC(=C1)CCC)O)CC=C(CCC=C(C)C)C LVJFXUFANJXUON-UHFFFAOYSA-N 0.000 claims 1
- FDAWPHAWDDMCSS-UHFFFAOYSA-N C(C(C)(C)C)(=O)OCOC1=C(C(=CC(=C1)CCCCC)O)CC=C(CCC=C(C)C)C Chemical compound C(C(C)(C)C)(=O)OCOC1=C(C(=CC(=C1)CCCCC)O)CC=C(CCC=C(C)C)C FDAWPHAWDDMCSS-UHFFFAOYSA-N 0.000 claims 1
- RNHYVSKRTWUUOC-UHFFFAOYSA-N C(C)(=O)OCOC1=C(C(=CC(=C1)CCCCC)O)CC=C(CCC=C(C)C)C Chemical compound C(C)(=O)OCOC1=C(C(=CC(=C1)CCCCC)O)CC=C(CCC=C(C)C)C RNHYVSKRTWUUOC-UHFFFAOYSA-N 0.000 claims 1
- LWZIUUUHJSPJKN-UHFFFAOYSA-N C(C)C(C(=O)OCOC1=C(C(=CC(=C1)CCCCC)O)CC=C(CCC=C(C)C)C)CC Chemical compound C(C)C(C(=O)OCOC1=C(C(=CC(=C1)CCCCC)O)CC=C(CCC=C(C)C)C)CC LWZIUUUHJSPJKN-UHFFFAOYSA-N 0.000 claims 1
- USXJYDDLRPJMDF-UHFFFAOYSA-N C(OC(C)OC1=C(C(=CC(=C1)CCCCC)O)CC=C(CCC=C(C)C)C)(OCC)=O Chemical compound C(OC(C)OC1=C(C(=CC(=C1)CCCCC)O)CC=C(CCC=C(C)C)C)(OCC)=O USXJYDDLRPJMDF-UHFFFAOYSA-N 0.000 claims 1
- QJQIPODPTNTTIC-UHFFFAOYSA-N C1(CCCCC1)OCOC=1C(=C(C=C(C=1)CCCCC)O)CC=C(CCC=C(C)C)C Chemical compound C1(CCCCC1)OCOC=1C(=C(C=C(C=1)CCCCC)O)CC=C(CCC=C(C)C)C QJQIPODPTNTTIC-UHFFFAOYSA-N 0.000 claims 1
- 125000004650 C1-C8 alkynyl group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 claims 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 claims 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 claims 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 claims 1
- MDUSLATWGBDRPU-UHFFFAOYSA-N CC(=CCC1=C(C=C(C=C1OC(C)(C)OC)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C=C1OC(C)(C)OC)CCCCC)O)CCC=C(C)C MDUSLATWGBDRPU-UHFFFAOYSA-N 0.000 claims 1
- BJCHCUUMDFWZMX-UHFFFAOYSA-N CC(=CCC1=C(C=C(C=C1OC(C)(C)OC)CCCCC)OC(C)(C)OC)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C=C1OC(C)(C)OC)CCCCC)OC(C)(C)OC)CCC=C(C)C BJCHCUUMDFWZMX-UHFFFAOYSA-N 0.000 claims 1
- HGOXGZZZXONPGN-UHFFFAOYSA-N CC(=CCC1=C(C=C(C=C1OC1(CCCC1)OC)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C=C1OC1(CCCC1)OC)CCCCC)O)CCC=C(C)C HGOXGZZZXONPGN-UHFFFAOYSA-N 0.000 claims 1
- RTPQYKFNYAENBQ-UHFFFAOYSA-N CC(=CCC1=C(C=C(C=C1OC1(CCCC1)OC)CCCCC)OC1(CCCC1)OC)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C=C1OC1(CCCC1)OC)CCCCC)OC1(CCCC1)OC)CCC=C(C)C RTPQYKFNYAENBQ-UHFFFAOYSA-N 0.000 claims 1
- FEHAOTODIILACB-UHFFFAOYSA-N CC(=CCC1=C(C=C(C=C1OCOC)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C=C1OCOC)CCCCC)O)CCC=C(C)C FEHAOTODIILACB-UHFFFAOYSA-N 0.000 claims 1
- ZQBZPUXEKDKXMH-UHFFFAOYSA-N CC(=CCC1=C(C=C(C=C1OCOC)CCCCC)OCOC)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C=C1OCOC)CCCCC)OCOC)CCC=C(C)C ZQBZPUXEKDKXMH-UHFFFAOYSA-N 0.000 claims 1
- FDANXMNLSKYTKH-UHFFFAOYSA-N CC(=CCC1=C(C=C(C=C1OCOCC)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C=C1OCOCC)CCCCC)O)CCC=C(C)C FDANXMNLSKYTKH-UHFFFAOYSA-N 0.000 claims 1
- VXUWXFQLLMPXJD-UHFFFAOYSA-N CC(=CCC1=C(C=C(C=C1OCOCC)CCCCC)OCOCC)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C=C1OCOCC)CCCCC)OCOCC)CCC=C(C)C VXUWXFQLLMPXJD-UHFFFAOYSA-N 0.000 claims 1
- OOFCLQKLVSRURP-UHFFFAOYSA-N CC(=CCC1=C(C=C(C=C1OCOCCOC)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C=C1OCOCCOC)CCCCC)O)CCC=C(C)C OOFCLQKLVSRURP-UHFFFAOYSA-N 0.000 claims 1
- BCBMSAQKIBJLSY-UHFFFAOYSA-N CC(=CCC1=C(C=C(C=C1OCOCCOC)CCCCC)OCOCCOC)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C=C1OCOCCOC)CCCCC)OCOCCOC)CCC=C(C)C BCBMSAQKIBJLSY-UHFFFAOYSA-N 0.000 claims 1
- BHRKWRMYOALMSB-UHFFFAOYSA-N COCCOCCOCCOCCOC(C)OC=1C(=C(C=C(C=1)CCCCC)O)CC=C(CCC=C(C)C)C Chemical compound COCCOCCOCCOCCOC(C)OC=1C(=C(C=C(C=1)CCCCC)O)CC=C(CCC=C(C)C)C BHRKWRMYOALMSB-UHFFFAOYSA-N 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 claims 1
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 102100033061 G-protein coupled receptor 55 Human genes 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010051920 Glomerulonephropathy Diseases 0.000 claims 1
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 101000871151 Homo sapiens G-protein coupled receptor 55 Proteins 0.000 claims 1
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 claims 1
- 101000829761 Homo sapiens N-arachidonyl glycine receptor Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 102100023414 N-arachidonyl glycine receptor Human genes 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010029412 Nightmare Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000026251 Opioid-Related disease Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 208000025535 REM sleep behavior disease Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 102000003566 TRPV1 Human genes 0.000 claims 1
- 206010043903 Tobacco abuse Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 101150016206 Trpv1 gene Proteins 0.000 claims 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
- 125000004069 aziridinyl group Chemical group 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- WVIIMZNLDWSIRH-UHFFFAOYSA-N cyclohexylcyclohexane Chemical compound C1CCCCC1C1CCCCC1 WVIIMZNLDWSIRH-UHFFFAOYSA-N 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000036546 leukodystrophy Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000178 monomer Chemical group 0.000 claims 1
- 102000051367 mu Opioid Receptors Human genes 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- DWLVWMUCHSLGSU-UHFFFAOYSA-M n,n-dimethylcarbamate Chemical compound CN(C)C([O-])=O DWLVWMUCHSLGSU-UHFFFAOYSA-M 0.000 claims 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- PWXJULSLLONQHY-UHFFFAOYSA-N phenylcarbamic acid Chemical compound OC(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-N 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 108020001612 μ-opioid receptors Proteins 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945669P | 2019-12-09 | 2019-12-09 | |
| US62/945,669 | 2019-12-09 | ||
| US202063074603P | 2020-09-04 | 2020-09-04 | |
| US63/074,603 | 2020-09-04 | ||
| US202063112970P | 2020-11-12 | 2020-11-12 | |
| US63/112,970 | 2020-11-12 | ||
| PCT/CA2020/051638 WO2021113958A1 (en) | 2019-12-09 | 2020-11-27 | Cannabinoid derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023505513A JP2023505513A (ja) | 2023-02-09 |
| JP2023505513A5 JP2023505513A5 (https=) | 2023-11-22 |
| JPWO2021113958A5 true JPWO2021113958A5 (https=) | 2023-11-22 |
Family
ID=76329189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534425A Pending JP2023505513A (ja) | 2019-12-09 | 2020-11-27 | カンナビノイド誘導体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230059582A1 (https=) |
| EP (1) | EP4073033A4 (https=) |
| JP (1) | JP2023505513A (https=) |
| WO (1) | WO2021113958A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3997098A4 (en) | 2019-07-12 | 2023-10-11 | Canopy Growth Corporation | CANNABINOIDS DERIVATIVES |
| WO2021007663A1 (en) | 2019-07-12 | 2021-01-21 | Canopy Growth Corporation | Cannabinoid derivatives |
| JP2022540586A (ja) | 2019-07-12 | 2022-09-16 | キャノピー グロウス コーポレイション | カンナビノイド誘導体 |
| WO2021062559A1 (en) | 2019-10-02 | 2021-04-08 | Canopy Growth Corporation | Cannabinoid derivatives |
| EP4065554A4 (en) | 2019-11-26 | 2024-01-10 | Canopy Growth Corporation | CANNABIGEROL DERIVATIVES AND THEIR USE AS CANNABINOID RECEPTOR MODULATORS |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| TWI894435B (zh) * | 2021-02-26 | 2025-08-21 | 日商丸善石油化學股份有限公司 | 縮醛化合物、含有該化合物之添加劑及含有該化合物之阻劑用組成物 |
| AU2022324615A1 (en) * | 2021-08-04 | 2024-02-15 | Demeetra Agbio, Inc. | Cannabinoid derivatives and their use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030073712A1 (en) * | 2001-07-23 | 2003-04-17 | Bing Wang | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| US8481085B2 (en) * | 2006-06-15 | 2013-07-09 | Gw Pharma Limited | Pharmaceutical compositions comprising cannabigerol |
| WO2009098287A1 (en) * | 2008-02-06 | 2009-08-13 | Noscira S.A. | Phenyl-prenyl derivatives, of marine and synthetic origin, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
| CA3119729A1 (en) * | 2018-10-10 | 2020-04-16 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
-
2020
- 2020-11-27 WO PCT/CA2020/051638 patent/WO2021113958A1/en not_active Ceased
- 2020-11-27 EP EP20897653.0A patent/EP4073033A4/en active Pending
- 2020-11-27 US US17/783,287 patent/US20230059582A1/en not_active Abandoned
- 2020-11-27 JP JP2022534425A patent/JP2023505513A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021000053A5 (https=) | ||
| JP6813626B2 (ja) | グルコシルセラミド合成酵素阻害剤の製造方法 | |
| JPWO2021113958A5 (https=) | ||
| JP7098651B2 (ja) | エリグルスタット及びその中間化合物の合成方法 | |
| WO2004074297A1 (ja) | アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤 | |
| IL287159B2 (en) | Small molecules agonists for FXR (farnesoid X receptor) and method for their preparation and use | |
| EP1961734B1 (en) | Amine compound and use thereof for medical purposes | |
| JP2011513285A (ja) | アゼチジン誘導化合物、この調製方法および該化合物の治療的使用 | |
| JP2014503478A (ja) | フィンゴリモドの調製のための中間の化合物およびプロセス | |
| MXPA02005328A (es) | Derivados de fenalquiloxi-fenilo novedosos. | |
| US6730803B2 (en) | Synthetic intermediate for epothilone derivative and production method thereof | |
| JPWO2021062557A5 (https=) | ||
| IL149517A (en) | Derivatives of phenyl are converted three times and analogues | |
| JPWO2021000054A5 (https=) | ||
| Gould et al. | The development of highly active acyclic chiral hydrazides for asymmetric iminium ion organocatalysis | |
| JPWO2021007663A5 (https=) | ||
| JPWO2021007660A5 (https=) | ||
| JPWO2021102567A5 (https=) | ||
| JPWO2021007662A5 (https=) | ||
| JP6001168B2 (ja) | フェニルアルキルスルファメート化合物及びこれを含む筋弛緩剤組成物 | |
| US20030119902A1 (en) | Novel aminobenzoephenones | |
| JPWO2021062559A5 (https=) | ||
| JPWO2021102568A5 (https=) | ||
| JPWO2021007661A5 (https=) | ||
| JPWO2021102569A5 (https=) |